ASMB

Assembly Biosciences, Inc.

54
Fundamentals66/ 100
Valuation50/ 100
Upside potential58/ 100
Risk potential30/ 100

ASMB's outlook is improving, though it still trails on the overall score.

LLY

Eli Lilly and Company

78
Fundamentals85/ 100
Valuation62/ 100
Upside potential72/ 100
Risk potential15/ 100

LLY has the edge over ASMB overall, supported by stronger fundamentals and lower modeled downside.

ASMB Fundamentals

MetricStatus
Healthy
Stable
Under pressure
Unavailable

ASMB's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.

LLY Fundamentals

MetricStatus
Healthy
Strong
Strong
Healthy

LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.

ASMB PE Valuation

CHEAPFAIREXPENSIVE97x193x290x387x
CHEAPFAIREXPENSIVE97x193x290x387x
LevelPEPriceVs current
Cheap19x$19.00-5.8%
Current20x$20.18—
Fair124x$124+513%
Expensive344x$344+1604%

Historical ranges are pointers, not guarantees.

ASMB has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.

LLY PE Valuation

CHEAPFAIREXPENSIVE37x74x111x147x
CHEAPFAIREXPENSIVE37x74x111x147x
LevelPEPriceVs current
Cheap27x$845-41%
Forward30x$1,427—
Current46x$1,427—
Fair48x$1,466+2.7%
Expensive85x$2,612+83%

Historical ranges are pointers, not guarantees.

LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.

ASMB Forward outlook

MetricOutlook
--
Losses shrinking
Strong growth
--
Limited
High

Analysts expect ASMB's losses to shrink, with revenue growing.

LLY Forward outlook

MetricOutlook
Strongly improving
Strong growth
Strong growth
Strongly improving
Limited
Moderate

Analysts expect strong earnings and revenue growth for LLY, with profitability improving.

ASMB Risk to reward

ScenarioChangePrice
Upside+42%$28.62
Downside-30%$14.10

Calculated from the latest close: $20.18 on Nov 12.

ASMB trails LLY on modeled risk to reward, with less potential upside relative to its potential downside.

LLY Risk to reward

ScenarioChangePrice
Upside+39%$1,988.49
Downside-15%$1,209.08

Calculated from the latest close: $1,427.28 on Nov 12.

LLY has a better modeled risk to reward balance than ASMB, with more potential upside relative to its potential downside.

ASMB Earnings Per Share

Q4 2023: $-13.38Q1 2024: $-10.60Q2 2024: $-8.74Q3 2024: $-7.01Q4 2024: $-6.69Q1 2025: $-6.20Q2 2025: $-5.55Q3 2025: $-4.76Q4 2025: $-0.55Q1 2026: $0.08Q2 2026: $1.21Q3 2026: $1.00
Q4 2023: $-13.38Q1 2024: $-10.60Q2 2024: $-8.74Q3 2024: $-7.01Q4 2024: $-6.69Q1 2025: $-6.20Q2 2025: $-5.55Q3 2025: $-4.76Q4 2025: $-0.55Q1 2026: $0.08Q2 2026: $1.21Q3 2026: $1.00
QuarterTTM EPSYoY
Q3 2026$1.00+$5.76
Q2 2026$1.21+$6.76
Q1 2026$0.08+$6.28
Q4 2025-$0.55+$6.14
Q3 2025-$4.76+$2.25
Q2 2025-$5.55+$3.19
Q1 2025-$6.20+$4.40
Q4 2024-$6.69+$6.69

ASMB has returned to profit: it earned $1.00 per share over the past year, after losing money the year before.

LLY Earnings Per Share

Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
QuarterTTM EPSYoY
Forward$46.82+52%
Q3 2026$30.81+51%
Q2 2026$29.80+95%
Q1 2026$28.15+129%
Q4 2025$22.95+96%
Q3 2025$20.44+121%
Q2 2025$15.30+88%
Q1 2025$12.29+81%
Q4 2024$11.71+102%

LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.

ASMB Quarterly Revenue

Q4 2023: --Q1 2024: $6MQ2 2024: $9MQ3 2024: $7MQ4 2024: $7MQ1 2025: $9MQ2 2025: $10MQ3 2025: $11MQ4 2025: $42MQ1 2026: $8MQ2 2026: $13MQ3 2026: $3M
Q4 2023: --Q1 2024: $6MQ2 2024: $9MQ3 2024: $7MQ4 2024: $7MQ1 2025: $9MQ2 2025: $10MQ3 2025: $11MQ4 2025: $42MQ1 2026: $8MQ2 2026: $13MQ3 2026: $3M
QuarterRevenueYoY
Q3 2026$3M-73%
Q2 2026$13.4M+39%
Q1 2026$8.2M-13%
Q4 2025$42.5M+477%
Q3 2025$10.8M+58%
Q2 2025$9.6M+13%
Q1 2025$9.4M+63%
Q3 2021$6.3M-82%

ASMB's revenue is growing: $3M last quarter, down 73% from the same quarter a year ago.

LLY Quarterly Revenue

Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
QuarterRevenueYoY
Q3 2026$24.4B+39%
Q2 2026$23B+48%
Q1 2026$19.8B+56%
Q4 2025$19.3B+43%
Q3 2025$17.6B+54%
Q2 2025$15.6B+38%
Q1 2025$12.7B+45%
Q4 2024$13.5B+45%

LLY has the edge over ASMB on sales, with more consistent year-over-year improvement.

ASMB Free Cash Flow

Q4 2023: $74MQ1 2024: −$18MQ2 2024: −$17MQ3 2024: −$15MQ4 2024: −$407,000Q1 2025: −$23MQ2 2025: −$17MQ3 2025: −$15MQ4 2025: $14MQ1 2026: −$22MQ2 2026: −$15MQ3 2026: −$17M
Q4 2023: $74MQ1 2024: −$18MQ2 2024: −$17MQ3 2024: −$15MQ4 2024: −$407,000Q1 2025: −$23MQ2 2025: −$17MQ3 2025: −$15MQ4 2025: $14MQ1 2026: −$22MQ2 2026: −$15MQ3 2026: −$17M
QuarterFree cash flowYoY
Q3 2026-$17.3M-$2.1M
Q2 2026-$15.5M+$1.3M
Q1 2026-$22.1M+$1.3M
Q4 2025$14.2M+$14.6M
Q3 2025-$15.2M+$69K
Q2 2025-$16.8M+$358K
Q1 2025-$23.4M-$5.1M
Q4 2024-$407K-101%

ASMB has burned cash in almost every quarter: −$41M over the past year, against −$56M the year before.

LLY Free Cash Flow

Q4 2023: −$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
Q4 2023: −$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
QuarterFree cash flowYoY
Q3 2026$8.2B+22%
Q2 2026$7.8B+458%
Q1 2026$3B+1826%
Q4 2025$677.9M-31%
Q3 2025$6.7B+186%
Q2 2025$1.4B+476%
Q1 2025$156.1M-13%
Q4 2024$977.8M+$2.4B

LLY has the edge over ASMB on cash generation, producing positive trailing cash flow while its opponent burns cash.

ASMB Total Shares

Q4 2023: 5MQ1 2024: 5MQ2 2024: 6MQ3 2024: 6MQ4 2024: 6MQ1 2025: 8MQ2 2025: 8MQ3 2025: 13MQ1 2026: 17MQ2 2026: 19MQ3 2026: 22M
Q4 2023: 5MQ1 2024: 5MQ2 2024: 6MQ3 2024: 6MQ4 2024: 6MQ1 2025: 8MQ2 2025: 8MQ3 2025: 13MQ1 2026: 17MQ2 2026: 19MQ3 2026: 22M
PeriodChange %Net change
Quarterly+16%+2.9M shares
1 year+184%+14.1M shares
3 years+400%+17.4M shares
5 years+510%+18.2M shares
Available history+895%+19.6M shares

ASMB has 22M diluted shares, up 184% from a year ago.

LLY Total Shares

Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
PeriodChange %Net change
Quarterly0%-300K shares
1 year-0.6%-5.4M shares
3 years-0.7%-6.4M shares
5 years-1.9%-17.4M shares
Available history-4.5%-42.3M shares

LLY has the edge over ASMB on shareholder dilution, with a more favorable share count trend.

ASMB Net Leverage

LLY Net Leverage

Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
QuarterNet LeverageStatus
Q3 20261.2xHealthy
Q2 20261.3xHealthy
Q1 20261.2xHealthy
Q4 20251.3xHealthy
Q3 20251.3xHealthy
Q2 20252.0xHealthy
Q1 20252.3xModerate
Q4 20242.1xModerate

LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.

ASMB Weekly Momentum

MetricValueStatus
RSI37.5Neutral
Stochastic5.7Oversold

ASMB's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).

LLY Weekly Momentum

MetricValueStatus
RSI68.3Neutral
Stochastic84.1Overbought

LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).

ASMB PE vs Healthcare Sector

MetricASMBSector medianRelative
PE20x26x22% below
PE %26293 pts below

ASMB has the edge over LLY on valuation relative to its sector.

LLY PE vs Healthcare Sector

MetricLLYSector medianRelative
PE46x26x79% above
PE %482919 pts above

LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.

ASMB Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$21.35.3% below
20 week MA$26.123% below
50 week MA$27.827% below
100 week MA$23.414% below
200 week MA$18.49.9% above

ASMB has fallen below most of its moving averages, though it's still 9.9% above its 200-week average.

LLY Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1,279.412% above
20 week MA$1,218.817% above
50 week MA$1,102.229% above
100 week MA$954.150% above
200 week MA$797.579% above

LLY has the edge over ASMB on trend strength, trading above more of its moving averages.

ASMB Yearly ROI

YearStart priceEnd priceROI
2020$251.3$74.4-70%
2021$74.4$27.2-63%
2022$27.2$15.1-44%
2023$15.1$9.84-35%
2024$9.84$15.2+54%
2025$15.2$33.6+122%
2026 YTD$33.6$20.2-40%

ASMB's yearly returns have swung widely, from +122% in 2025 to −70% in 2020. It's down 40% so far in 2026.

LLY Yearly ROI

YearStart priceEnd priceROI
2020$131.5$166.7+27%
2021$166.7$273.1+64%
2022$273.1$367.9+35%
2023$367.9$582.9+58%
2024$582.9$783.2+34%
2025$783.2$1,077.8+38%
2026 YTD$1,077.8$1,427.3+32%

LLY has the edge over ASMB on returns for 2026, with the stronger performance.

Give your agent the market.

Get API key